Cargando…

Oligonucleotides—A Novel Promising Therapeutic Option for IBD

Inflammatory Bowel Diseases (IBD), whose denomination comprehends Crohn's Disease (CD) and Ulcerative Colitis (UC), are intestinal chronic diseases that often require lifelong medical therapy. In the last two decades monoclonal antibodies against the cytokine TNF have become integral parts in t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scarozza, Patrizio, Schmitt, Heike, Monteleone, Giovanni, Neurath, Markus F., Atreya, Raja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6491809/ https://www.ncbi.nlm.nih.gov/pubmed/31068803 http://dx.doi.org/10.3389/fphar.2019.00314

Ejemplares similares

Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?
por: Monteleone, Giovanni, et al.
Publicado: (2022)

IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality
por: Atreya, Raja, et al.
Publicado: (2022)

Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?
por: Atreya, Raja, et al.
Publicado: (2020)

Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab
por: Scarozza, Patrizio, et al.
Publicado: (2020)

Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease
por: Di Fusco, Davide, et al.
Publicado: (2019)

Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study
por: Mühl, Laura, et al.
Publicado: (2021)

Role of the IL23/IL17 Pathway in Crohn’s Disease
por: Schmitt, Heike, et al.
Publicado: (2021)

Editorial: IBD Management—Novel Targets and Therapeutic Perspectives
por: Antonioli, Luca, et al.
Publicado: (2020)

Functional Molecular Network Analysis Enables Prediction of Response to Vedolizumab Therapy in Anti-TNF Refractory IBD Patients
por: Breidert, Matthias, et al.
Publicado: (2020)

Antisense oligonucleotide is a promising intervention for liver diseases
por: Lu, Kailing, et al.
Publicado: (2022)

COVID-19 and immunomodulation in IBD
por: Neurath, Markus F
Publicado: (2020)

Antisense oligonucleotide: A promising therapeutic option to beat COVID‐19
por: Quemener, Anaïs M., et al.
Publicado: (2021)

Role of Interleukin-34 in Cancer
por: Franzè, Eleonora, et al.
Publicado: (2020)

Novel Small Molecules in IBD: Current State and Future Perspectives
por: Jefremow, André, et al.
Publicado: (2023)

Deciphering Novel Mechanistic and Pharmacokinetic Effects of Tofacitinib in Intestinal Inflammation: Expect the Unexpected
por: Atreya, Raja, et al.
Publicado: (2021)

Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma
por: Zundler, Sebastian, et al.
Publicado: (2023)

The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis
por: Schmitt, Heike, et al.
Publicado: (2020)

Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases
por: Marafini, Irene, et al.
Publicado: (2020)

Hsp60 as a Novel Target in IBD Management: A Prospect
por: Cappello, Francesco, et al.
Publicado: (2019)

Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?
por: Sisay, Mekonnen
Publicado: (2020)

Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease
por: Lichnog, Charlotte, et al.
Publicado: (2019)

Cyclin-Dependent Kinase Inhibitors and Their Therapeutic Potential in Colorectal Cancer Treatment
por: Thoma, Oana-Maria, et al.
Publicado: (2021)

Antisense oligonucleotides: a novel Frontier in pharmacological strategy
por: Collotta, D., et al.
Publicado: (2023)

Editorial: Microbiome in IBD: From Composition to Therapy
por: Zhu, Ruixin, et al.
Publicado: (2021)

Natural History of Ulcerative Colitis with Coexistent Colonic Diverticulosis
por: Marafini, Irene, et al.
Publicado: (2021)

Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias
por: Lopes, Bruno A., et al.
Publicado: (2022)

Endoscopic Therapy in Inflammatory Bowel Diseases
por: Neumann, Helmut, et al.
Publicado: (2015)

Mild COVID-19 Symptoms in an Infliximab-Treated Ulcerative Colitis Patient: Can Ongoing Anti-TNF Therapy Protect against the Viral Hyperinflammatory Response and Avoid Aggravated Outcomes?
por: Abdullah, Abdullah, et al.
Publicado: (2020)

COVID-19 Therapeutic Options Under Investigation
por: Kaddoura, Malak, et al.
Publicado: (2020)

Topical Therapeutic Options in Corneal Neuropathic Pain
por: Nortey, Jeremy, et al.
Publicado: (2022)

Novel Peptide Conjugates of Modified Oligonucleotides for Inhibition of Bacterial RNase P
por: Novopashina, Darya, et al.
Publicado: (2019)

Targeting the Eph/Ephrin System as Anti-Inflammatory Strategy in IBD
por: Grandi, Andrea, et al.
Publicado: (2019)

Claudins: Beyond Tight Junctions in Human IBD and Murine Models
por: Čužić, Snježana, et al.
Publicado: (2021)

Editorial: Microbiome in IBD: From Composition to Therapy, Volume II
por: Liu, Ning-Ning, et al.
Publicado: (2023)

All are Equal, Some are More Equal: Targeting IL 12 and 23 in IBD – A Clinical Perspective
por: Jefremow, André, et al.
Publicado: (2020)

Nanocurcumin: A Promising Candidate for Therapeutic Applications
por: Karthikeyan, Adhimoolam, et al.
Publicado: (2020)

Plant-Derived Compounds as Promising Therapeutics for Vitiligo
por: Pang, Yaobin, et al.
Publicado: (2021)

Ferroptosis as a promising therapeutic strategy for melanoma
por: Ta, Na, et al.
Publicado: (2023)

Pharmacokinetic Studies of Antisense Oligonucleotides Using MALDI-TOF Mass Spectrometry
por: Herkt, Markus, et al.
Publicado: (2020)

Role of Pyroptosis in Inflammatory Bowel Disease (IBD): From Gasdermins to DAMPs
por: Zhang, Shuxia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_96qfv41rpvngjk4qpfr05hkg45